Spartan Planning & Wealth Management Invests $230,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Spartan Planning & Wealth Management bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,493 shares of the biopharmaceutical company’s stock, valued at approximately $230,000.

Other hedge funds have also modified their holdings of the company. nVerses Capital LLC acquired a new position in Gilead Sciences in the 3rd quarter valued at $25,000. Valued Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares in the last quarter. Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences in the second quarter worth approximately $33,000. Cedar Wealth Management LLC boosted its holdings in Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 160 shares in the last quarter. Finally, Friedenthal Financial purchased a new position in Gilead Sciences during the 3rd quarter worth approximately $50,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the sale, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 453,734 shares of company stock worth $41,902,086 in the last quarter. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded down $0.24 during midday trading on Tuesday, reaching $90.99. 2,546,406 shares of the company traded hands, compared to its average volume of 4,236,046. The stock’s 50-day simple moving average is $91.86 and its 200-day simple moving average is $82.84. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The firm has a market cap of $113.40 billion, a PE ratio of 1,011.00, a PEG ratio of 2.24 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the previous year, the business earned $2.29 EPS. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.38%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Royal Bank of Canada reiterated a “sector perform” rating and set a $84.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Daiwa America raised Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Barclays lifted their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research note on Thursday, November 7th. Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Twelve investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $96.43.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.